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RESUMO
Introdução: Esclerite é uma doença grave, rara e progressiva, que envolve inflamação e
edema dos tecidos episcleral superficial, profundo e escleral e está associada com doenças
sistêmicas reumatológicas em muitos casos.
Objetivos: Realizar um estudo prospectivo comparativo entre as manifestações oftal-
mológicas, achados sorológicos e resposta terapêutica de pacientes com esclerite isolada
e com esclerite associada a doenças sistêmicas reumatológicas.
Métodos: Trinta e dois pacientes com esclerite não infecciosa participaram do estudo, de
março de 2006 a março de 2008. O tratamento realizado baseou-se no uso de colírios de
corticoides associados aos anti-inflamatórios não-hormonais, seguidos de corticoides
sistêmicos e imunossupressores, se necessário. O sucesso do tratamento foi considerado
como seis meses sem crises de esclerite.
Resultados: Quatorze dos 32 pacientes apresentaram esclerite associada à doença
sistêmica, dos quais nove com artrite reumatóide, dois com lúpus eritematoso sistêmico,
um com doença de Crohn, um com doença de Behçet e um com gota. Não houve
diferenças em relação ao envolvimento ocular e suas complicações, predominando a
esclerite anterior nodular e o afinamento escleral, respectivamente. O grupo com esclerite
associada a doenças sistêmicas apresentou 64,3% de positividade de autoanticorpos
contra 27,8% no grupo com esclerite isolada, sendo tal diferença estatisticamente
significante. No grupo com esclerite isolada, 16,7% fez uso de apenas anti-inflamatórios,
33,3% de corticoide sistêmico, 27,8% de corticoide com um imunossupressor, 5,5% dois
imunossupressores, 16,7% corticoide com dois imunossupressores e 33,3% pulsoterapia
com imunossupressor; sendo que houve sucesso do tratamento em 88,9%. No grupo com
esclerite associada à doença sistêmica, 7,1% fez uso de anti-inflamatórios, 7,1% corti-
coide sistêmico, 50% corticoide com um imunossupressor, 7,1% dois imunossupressores
e 22,2% pulsoterapia com imunossupressor; com 100% de sucesso no tratamento nesse
grupo.
Conclusão: Em ambos os grupos houve predomínio da esclerite nodular unilateral e o
grupo com esclerite associada a doença sistêmica apresentou taxas maiores de todos os
autoanticorpos testados. Não houve diferença entre os grupos em relação ao uso de
imunossupressores e à resposta terapêutica, a qual foi totalmente satisfatória no grupo
com esclerite associada à doença sistêmica e satisfatória no grupo com esclerite isolada.
Descritores: Esclerite; Doenças reumáticas; Autoanticorpos; Inflamação; Imunossupressores
ABSTRACT
Introduction: Scleritis is a rare, progressive and serious disease, the signs of which
are inflammation and edema of episcleral and scleral tissues and is greatly associated
with systemic rheumatoid diseases.
Purpose: To perform a prospective and comparative study between ophthalmologic
manifestations, serologic findings and therapeutic response of patients with isolated
scleritis and scleritis associated with systemic rheumatoid disease.
Methods: Thirty-two outpatients with non-infectious scleritis were studied, from March
2006 to March 2008. The treatment was corticoid eye drops associated with anti-
inflammatory agents, followed by systemic corticoids and immunosuppressive drugs
if necessary, was considered successful after six months without scleritis recurrence.
Results: Fourteen of 32 patients had scleritis associated with systemic rheumatoid
disease, of which nine had rheumatoid arthritis, two systemic lupus erythematosus,
one Crohn’s disease, one Behçet’s disease and one gout. There were no difference in
relation to involvement and ocular complications, there was predominance of nodular
anterior scleritis and scleral thinning was the most frequent complication. The scleritis
associated with systemic rheumatoid disease group had 64.3% of autoantibodies,
versus 27.8% among those with isolated scleritis and this difference was statistically
significant. In the isolated scleritis group 16.7% used anti-inflammatory, 33.3% corti-
costeroids, 27.8% corticosteroids with one immunosuppressive drug, 5.5% two im-
munosuppressive drugs, 16.7% corticosteroids with two immunosuppressive drugs
and 33.3% pulse of immunosuppressive drugs, there was remission in 88.9%. In the
scleritis associated with systemic rheumatoid disease group 7.1% used anti-inflam-
matory, 7.1% corticosteroids, 50% corticosteroids with one immunosuppressive drug,
7.1% two immunosuppressive drugs and 22.2% pulse of immunosuppressive drugs,
100% had treatment success.
Conclusion: Prevalence of unilateral nodular scleritis was noted in both groups and
higher rates of all the parameters tested were noted in the scleritis associated with
systemic rheumatoid disease group. There were no differences between the groups
with respect to the use of immunosuppressive drugs and therapeutic response, which
was fully satisfactory in the scleritis associated with systemic rheumatoid disease
group and satisfactory in the isolated scleritis group.
Keywords: Scleritis; Rheumatic diseases; Autoantibodies; Inflammation; Immunosup-
pressive agents
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INTRODUCTION
Scleritis is a rare, progressive and serious disease, the signs of
which are inflammation and edema of superficial episcleral tissues.
Clinical and epidemiological characteristics include: severe ocular
pain radiating to the ipsilateral side, redness of the sclera and con-
junctiva, sometimes changing to a purple hue, affects mostly young
and middle aged women and is generally bilateral(1). This disease is
difficult to treat and can progress with serious complications if not
done adequately(2,3). Identifiable causes for scleritis include surgical
trauma, bacterial, viral and parasitic infections, autoimmune diseases
and primary vasculitis. However, an underlying systemic disease is not
identified for the vast majority of cases of scleritis, even after clinical
and laboratory tests(4). Scleritis is greatly associated with systemic
rheumatoid disease (30 to 50%), especially rheumatoid arthritis (RA),
Wegener’s granulomatosis, nodular polyarthritis and systemic lupus
erythematosus (SLE)(5-7). Rarely scleritis is a part of the systemic invol-
vement of infectious diseases (about 5 to 10%)(8).
Patients with scleritis do not usually respond well to topical
therapies involving corticoids and non hormonal anti-inflammatory
drugs (NSAIDs). However, some patients respond well to the non
hormonal anti-inflammatory drugs, and these medications are pres-
cribed for the initial treatment of non necrotizing scleritis. A great
number of cases of scleritis require the use of systemic corticoids and
about 25% require the use of associated immunosuppressive
agents to control the inflammation(2,9-11).
The aim of this work was to perform a comparative study bet-
ween ophthalmologic manifestations, serologic findings and the-
rapeutic response of patients with isolated scleritis and scleritis
associated with systemic rheumatoid disease.
METHODS
CASUISTIC
Thirty-two outpatients were consecutively selected from the
External Disease and Cornea sector of the Department of Ophthal-
mology, UNIFESP. Patients from both genders diagnosed with
non-infectious scleritis were included from the period of March
2006 to March 2008. Patients who gave consent for participation
were submitted to a protocol consisting of clinical and ophthal-
mologic evaluation. We used the criteria established by Watson et
al.(12) for scleritis diagnosis and classification: anterior diffuse scle-
ritis, nodular scleritis, necrotizing scleritis and posterior scleritis. In
order to diagnose rheumatologic disease, all patients were evalua-
ted by the same rheumatologist, and systemic disease diagnosis
was carried out according to The American College of Rheumato-
logy Classification Criteria specific for each disease(13). The time period
of the disease was defined as the period from the first scleritis-
related clinical symptom to the present date.
METHODOLOGY
Laboratory examinations were performed to test for autoanti-
bodies as follows: antinuclear antibodies (ANA) were assayed using
the indirect immunofluorescence assay (IFA) with HEp-2 cells as the
substrate (Hemagen, Whalton, MD)(14), rheumatoid factor (RF) was
assayed using the latex particle agglutination test(15), anti-neutro-
phil cytoplasmic antibody, c-ANCA and p-ANCA were assayed using
the human neutrophil IIF technique(16), and anti-perinuclear factor
(APF) antibodies were assayed using the protocol proposed by Hoet(17)
for IIF. Other examinations performed were: erythrocyte sedimen-
tation rate using the Westergren technique, complete blood count
and urine type I test. Some patients were submitted to chest and
hand X-rays when necessary.
TREATMENT
The scleritis treatment organogram from the Cornea and Exter-
nal Disease ambulatory (Department of Ophthalmology, UNIFESP)
was followed. This treatment starts with corticoid eye drops asso-
ciated with NSAID, followed by the use of systemic corticoids(18).
Patients who continued to have eye inflammation (red eye or eye
pain) were further treated with immunosuppressors such as metho-
trexate (MTX) 7.5 to 15 mg/week, azathioprine (AZA) 100 mg/day,
cyclosporine A (CsA) 3.0 to 5.0 mg/kg/day, mycophenolate mofetil
2 g/day, clorambucil 0.1 mg/kg/day, leflunomide 20 mg/day or cyclo-
phosphamide pulse therapy of 15/mg/day once a month for four
months(19). Due to the varying degree of disease severity, the organo-
gram was not always followed. The organogram was also not follo-
wed in the case of patients with other associated rheumatic disea-
ses already undergoing treatment with corticoids and/or immuno-
suppressors. In a few more severe cases, the patients received pulse
therapy with corticoids, subconjunctival corticoids or biological the-
rapy (adalimumab)(20-22).
The treatment was considered successful after a period of six
months without scleritis recurrences and without clinical symptoms.
The data collected from the clinical and laboratory tests were
evaluated for statistical analysis. The following statistical analysis
were carried out: Mann-Whitney test for comparing groups accor-
ding to age, chi-squared test and the Fisher exact test for analyzing
the data presented in 2x2 tables. Chi-square tests were performed
using a rejection level of p<0.05 (or 5%), and significant values are
marked with an asterisk.
RESULTS
A total of 32 patients diagnosed with scleritis were evaluated
at the External Diseases and Cornea ambulatory from the Depart-
ment of Ophthalmology, UNIFESP during the period of this study.
Clinical evaluation and laboratory tests diagnosed 18 (56.25%) pa-
tients with isolated scleritis (IS) and 14 (43.75%) patients with scle-
ritis associated with systemic disease (SASD), of which 9 had RA, 2 had
SLE, 1 had Crohn’s disease, 1 had Behçet’s disease and 1 had gout.
The average duration of the SASD group was 6.8 years, ranging
from zero to 33 years. The average age for the IS group was 58.4
years old (ranging from 25 to 79 years), and was slightly higher than
the average age for the SASD group which was 54.2 years old
(ranging from 16 to 81 years). The female gender predominated
for both groups; 66.7% and 78.6%, respectively.
Characteristics of the afflicted eye are displayed in table 1. No
differences can be observed between groups regarding eye invol-
vement patterns, and in both cases, there’s a predominance of
anterior nodular scleritis.
Table 1. Patient distribution according to patterns of ocular
involvement
Scleritis IS SASD
Nº % Nº %
Diffuse anterior 01 005.6 03 021.4
OD only 00 00 01 033.3
OS only 01 100.0 00 0
OU 00 00 02 066.7
Nodular anterior 17 094.4 11 078.6
OD only 05 029.4 05 045.5
OS only 07 041.2 05 045.5
OU 05 029.4 01 009.0
Necrotizing 00 00 00 0
Posterior 00 00 00 0
Total 18 100.0 12 100.0
 OD= right eye; OS= left eye; OU= both eyes; IS= immunosupressor; SASD= scleritis
associated with systemic disease
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 The average duration of the eye disease was 4.9 years for the IS
group (ranging from 2 to16 years) and 3 for the SASD group (ranging
from 1 to 6 years). Eye complications presented by the patients
during the course of the disease are summarized in table 2. No
differences were found between groups regarding the presence
of complications or considering the type of complications presen-
ted, and scleral thinning was the most frequent eye alteration found
for both groups.
Laboratory tests showed that autoantibodies were present
although no differences were observed between groups. Howe-
ver, autoantibody titres varied between groups. Three patients in
the IS group were ANA positive (all with titres of 1/80 - fine speckled
pattern), one was RF positive (1/80) and one was p-ANCA positive
(1/80). In the SASD group, four patients were positive for ANA
(titres of 1/1280 - coarse speckled pattern, 1/1280 - homogeneous
pattern, 1/640 - fine speckled pattern and 1/80 - coarse standard
dotted), four cases were RF positive (1/640, 1-64, 86.10 and 74),
two patients were p-ANCA positive and two were APF positive.
TREATMENT USED FOR THE PATIENTS WITH ISOLATED SCLERITIS
Systemic medication was used for the treatment of scleritis in 17
of the 18 patients. A summary of the treatments used in this group
are listed in table 3, which also shows the medications used before
and after the patients enrolled in the External Diseases and Cornea
ambulatory, from the Department of Ophthalmology, UNIFESP.
The success rate for this treated group was 88.9%, therefore in
two patients recurrence of the scleritis occurred in less than six
months. Recurrence occurred in the first patient once the dose of
corticoids was reduced to less than 20 mg/day, even when asso-
ciated with other immunosuppressors such as clorambucil, AZA
Table 2. Ocular complications
Ocular complications IS SASD
Present 13 (72.2%) 09 (64.3%)
Corneal thinning 04 1
Scleral thinning 10 7
Cataract 04 2
Punctate keratitis 01 3
Adenoviral conjunctivitis 00 1
Glaucoma 01 0
Stromal infiltration 01 1
Maculopathy 00 1
Dry eyes 00 3
Corneal perforation 01 0
Absent 05 (27.8%) 05 (35.7%)
Total 18 (100%) 12 (100%)
IS= immunosupressor; SASD= scleritis associated with systemic disease
Table 3. Therapeutic history and clinical evolution of patients with isolated scleritis
Initial systemic Systemic medication taken Treatment Therapeutic
Patient medication  during disease evolution scheme response
01 Prednisone Prednisone SC Absence of inflammation
02 Prednisone Deflazacort SC Recurrence, followed by
a decrease in inflammation
03 Prednisone Prednisone and AZA SC + one IS Absence of inflammation
04 Prednisone and MTX Prednisone and MTX SC + one IS Absence of inflammation
05 Prednisone, AZA and CsA Prednisone, AZA and CsA SC + two IS Absence of inflammation
06 Prednisone and clorambucil Prednisone, MTX, SC+ two IS Presented successive inflammations
clorambucil, AZA, CsA,
triancinolone SC (1x),
betamethasone IM (1x)
07 Prednisone and etoricoxib Prednisone SC Absence of inflammation
08 Prednisone Prednisone SC Recurrence after not taking prednisone
on patient’s own account, followed by
a decrease in inflammation
09 Prednisone and Prednisone SC Recurrence after decreasing the
cyclophosphamide pulse (1x)  dose of prednisone, followed by
a decrease in inflammation
10 Prednisone and AZA AZA, CsA and Two IS Decrease in inflammation
methylprednisolone SC (1x)
11 Prednisone, betamethasone IM (1x) Prednisone, chloroquine diphosphate SC + one IS Decrease in inflammation
12 Prednisone Prednisone and MTX SC + one IS Presented successive inflammations
13 Prednisone, AZA, CsA and Prednisone, AZA, CsA, SC + two IS Recurrence, followed by
cyclophosphamide pulse (3x) methylprednisolone SC (1x), a decrease in inflammation
cyclophosphamide pulse (1x)
14 Indometacine Indometacine NSAID Absence of inflammation
15 Etoricoxib Etoricoxib NSAID Absence of inflammation
16 Prednisone Prednisone SC Recurrence and diagnosis
of episcleritis, followed by
a decrease in inflammation
17 Prednisone, AZA, CsA, MTX, Prednisone, mycophenolate mofetil, SC + one IS Presented several successive
cyclophosphamide pulse (9x) cyclophosphamide pulse (1x),  occurrences followed by
betamethasone IM (3x)  a decrease in inflammation
18 No systemic medication No systemic medication No systemic medication Absence of inflammation
SC= systemic corticoid; IS= immunosupressor; NSAID= non steroidal anti-inflammatory drug; IM= intramuscular; pulse= pulse therapy; MTX= methotrexate; AZA= azathioprine; CsA=
cyclosporine A
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Table 4. Therapeutic history and clinical evolution of patients with scleritis associated with systemic disease
Systemic Initial systemic Systemic medication taken Treatment Therapeutic
Patient disease medication  during disease evolution scheme response
01 RA Prednisone Prednisone SC Absence of inflammation
02 RA Prednisone Prednisone and MTX SC + one IS Absence of inflammation
03 RA Prednisone, MTX, Prednisone, MTX, sulfasalazine, SC + two IS Presented successive recurrences
sulfasalazine, MTX SC (2x) cyclophosphamide pulse (5x), (some two months after not taking
methylprednisolone SC (1x), MTX on patient’s own accord) followed
leflunomide, ciprofloxacin  by a decrease in inflammation
04 RA Prednisone and MTX Prednisone and MTX SC + one IS Absence of inflammation
05 RA Prednisone Prednisone and leflunomide SC + one IS Absence of inflammation
06 RA Prednisone, chloroquine Prednisone, chloroquine, SC + two IS + BT Decrease in inflammation
and leflunomide leflunomide, cyclophosphamide
pulse (1x), adalimumab
07 RA MTX, cyclobenzaprine, Prednisone, MTX SC + one IS + BT Presented two recurrences after
adalimumab  and adalimumab taking a decreased dose of
prednisone, followed by
a decrease in inflammation
08 RA Prednisone Prednisone and MTX SC + one IS Decrease in inflammation
09 RA Indometacine and MTX SC (2x) Prednisone and MTX SC + one IS Decrease in inflammation
10 SLE Prednisone, cyclophosphamide Prednisone and AZA SC + one IS Absence of inflammation
and triamcinolone SC (1x)
11 SLE MTX and chloroquine MTX and chloroquine two IS Absence of inflammation
12 Crohn’s Prednisone, AZA Prednisone and AZA SC + one IS Absence of inflammation
disease and mesalazine
13 Behçet’s No systemic Prednisone, MTX, AZA, SC + one IS Presented successive recurrences
disease medication thalidomide, colchicine followed by a decrease in inflammation
14 Gout No systemic medication Indometacine NSAID Absence of inflammation
RA= rheumatoid arthritis; SLE= systemic lupus erythematosus; SC= systemic corticoid; pulse= pulse therapy; BT= biological therapy; NSAID= non steroidal anti-inflammatory
drug; MTX= methotrexate; AZA= azathioprine; CsA= cyclosporine A
and MTX, and occurred in the second patient after taking lower
doses of corticoids, even when associated with MTX.
TREATMENT USED FOR PATIENTS WITH SCLERITIS ASSOCIATED
WITH SYSTEMIC DISEASE
Only three of the fourteen patients with SASD were not already
taking systemic medication when diagnosed with scleritis. After
diagnostic testing, RA, Behçet’s disease and gout were confirmed
in these patients, while the other patients had already been diag-
nosed and were undergoing treatment for their respective scle-
ritis associated systemic diseases. Even though the patients were
taking corticoids and/or immunosuppressors, they all presented
inflammation of the sclera. Table 4 summarizes the distribution of
the systemic diseases, the treatments used and the medication the
patients were taking before and after being enrolled in the am-
bulatory practices of the External Diseases and Cornea Sector, from
the Department of Ophthalmology, UNIFESP.
One of the patients with RA presented secondary systemic
infection from the use of immunosuppressors and was treated with
500 mg ciprofloxacin twice a day for seven days.
An alternative scheme was used for the patient with Behçet’s
disease; AZA associated with prednisone, which controlled the
patient’s clinical ocular manifestations. Later on, both medications
were discontinued due to gastric intolerance, and substituted with
thalidomide, which controlled mucous manifestations (oral and
genital). This patient developed neuritis as a result of the medica-
tion, which was then suspended. Subsequently, this patient suffe-
red an ocular crisis, muscular pains and reappearance of oral and
genital ulcers which were treated with prednisone and AZA.
In this group, recurrence did not occur in any of the patients
during the six months following the end of the treatment, which
therefore characterises this treatment as 100% successful.
ADVERSE EFFECTS
One patient from the IS group presented side effects due to
the use of prednisone, one due to AZA and one due to the use of
CsA and AZA. One patient from the SASD group presented side
effects due to the use of AZA.
DISCUSSION
Fourteen of the thirty-two patients studied (43.75%) had an
underlying scleritis associated systemic disease, a higher percen-
tage than that found in the recent literature(23,24).
The female gender prevailed in both groups involved in this
study; 66.7% in the IS group and 78.6% in the SASD group. Lite-
rature also shows a prevalence of female patients(3,25).
The average age of patients in the IS group was higher than
that of the SASD group; 58.4 and 54.2 years old, respectively. These
averages were higher than and diverged from those found in
recent literature, which shows a higher average age for patients in
the SASD group compared to the IS group; 55.24 and 48.29 years
old, respectively(6).
In regards to ocular manifestations, unilateral nodular scleritis
predominated in both groups. Recent literature shows a prevalen-
ce of diffuse scleritis, however with unilateral involvement prevai-
ling(6). After extensive research in scientific literature, we could not
find a scale or classification for ocular inflammation, thus, we used
the clinical symptoms (red eye and ocular pain) as parameters for
improvement or worsening of the ocular inflammation. In the same
way, we could not find a consensus in the literature about the
period in which the patient must be asymptomatic for considering
treatment success, then, we considered six months, by our clinical
experience.
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Patients in the IS group had been diagnosed with ocular disease
for a longer period of time than those from the SASD group; 4.9
and 3 years, respectively.
In the IS group, 72.2% presented ocular complications and in the
SASD group, 64.3%; however this difference did not show statistical
significance. Scleral thinning prevailed in both groups, which is in
accordance with previous studies in literature(3). In our study, all the
cases of cataract were caused by de use of corticoids and the cases of
corneal perforation were related to corneal melting.
The prevailing systemic disease in the SASD group was AR
(64.4%). This finding is in accordance with literature which identifies
RA as the main systemic disease associated with scleritis(1).
There were statistically significant differences between the
two groups regarding the laboratory tests; the SASD group in-
dicated a higher proportion of positive results for the parameters
tested, this is an important finding that should be considered in
the investigation of patients with scleritis. This group presented
positive ANA in 28.6% of the cases, positive RF in 28.6%, positive
APF in 14.3% and p-ANCA positive in 14.3%. The IS group presen-
ted positive ANA in 16.7% of the cases, positive RF in 5.5% and
positive p-ANCA in 5.5%. Data from the literature show that a signi-
ficant percentage of patients with scleritis are positive for ANCA, and
these patients are more likely to have severe ocular disease and
undiagnosed systemic disease associated(26,27). APF is considered an
important marker for the diagnosis of rheumatoid arthritis(28). The
initial treatment for scleritis is based on controlling the ocular
inflammatory crisis. As such, protocol establishes an initial treat-
ment with NSAID, followed by systemic corticoids and immuno-
suppressive agents in more complicated cases in order to control
the disease(29).
Regarding the behavior of scleritis and therapeutic response,
both groups showed similar results, independently of the systemic
disease. Patients with and without associated systemic disease
were likely to require systemic therapy (94.4% and 100%, respec-
tively), as related in recent literature(30). During the therapeutic
follow-up of IS patients, the medications used during a crisis were
maintained, trying to reduce or even suspend at first the use of
systemic corticoids, followed by the immunosuppressors(8,31-34). For
the treatment of SASD the aim is to change the initial treatment
according to the underlying disease, and in some cases adequate
treatment for the systemic disease already improves the ocular
disease(4,35). Alternatively, biological therapies may be used for
cases that do not respond to these treatment schemes(36,37).
CONCLUSION
In regards to ocular manifestations, we observed a prevalence
of unilateral nodular scleritis in both groups. Serologically, we
observed higher positive results for all laboratory parameters
tested in the SASD group. The therapeutic contribution was greatly
satisfactory for the SASD group with 100% therapeutic success,
while the IS group presented an 88.9%. In this study, there were no
differences between the two groups in relation to the eye com-
promising and the therapeutic response.
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